USPTO serial 78802619
VERENTA PHARMACEUTICALS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- ANKRAH, NAAKWAMA S
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with VERENTA PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; Astringents; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Drug delivery agents consisting compounds that facilitate delivery of a wide range of pharmaceuticals; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Inhalers filled with prodrugs, steroids, beta-agonists, anti- inflammatories or combinations thereof; Injectable pharmaceuticals for treatment of anaphylactic reactions; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations namely, anticoagulants; Pharmaceutical preparations namely, antidepressants; Pharmaceutical preparations namely, appetite suppressants; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Plant extracts for medical, veterinary and pharmaceutical purposes; Potassium preparations for pharmaceutical purposes; Synthetic peptides for pharmaceutical purposes; Unit dose capsules sold empty for pharmaceutical use; Vitamin and mineral preparations for use as ingredients in the food and pharmaceutical industry | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 5, 2008 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 5, 2008 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 26, 2007 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 27, 2007 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 27, 2007 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 3, 2007 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 14, 2007 | NPUB | NOTICE OF PUBLICATION | — |
| Feb 16, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 16, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 16, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 16, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 16, 2007 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 16, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 11, 2007 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jan 22, 2007 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Dec 27, 2006 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 27, 2006 | ALIE | ASSIGNED TO LIE | — |
| Dec 8, 2006 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 8, 2006 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 8, 2006 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 8, 2006 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 8, 2006 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Dec 8, 2006 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 19, 2006 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Oct 27, 2006 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Oct 12, 2006 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 6, 2006 | ALIE | ASSIGNED TO LIE | — |
| Oct 4, 2006 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 4, 2006 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 4, 2006 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 4, 2006 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 4, 2006 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 27, 2006 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 14, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 14, 2006 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 24, 2006 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 24, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 19, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 4, 2006 | MDSC | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Feb 3, 2006 | NWAP | NEW APPLICATION ENTERED | — |